3,653
Views
22
CrossRef citations to date
0
Altmetric
Review

Quantitative Translational Modeling to Facilitate Preclinical to Clinical Efficacy & Toxicity Translation in Oncology

Article: FSO306 | Received 19 Dec 2017, Accepted 12 Mar 2018, Published online: 23 Apr 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Elena M. Tosca, Roberta Bartolucci, Paolo Magni & Italo Poggesi. (2021) Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity. Expert Opinion on Drug Discovery 16:11, pages 1365-1390.
Read now

Articles from other publishers (21)

Bruna Scheuher, Khem Raj Ghusinga, Kimiko McGirr, Maksymilian Nowak, Sheetal Panday, Joshua Apgar, Kalyanasundaram Subramanian & Alison Betts. (2023) Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs). Journal of Pharmacokinetics and Pharmacodynamics.
Crossref
Vincent Lemaire, David Bassen, Mike Reed, Roy Song, Samira Khalili, Yi Ting (Kayla) Lien, Lu Huang, Aman P. Singh, Spyros Stamatelos, Dean Bottino & Fei Hua. (2022) From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology Modeling in Cancer Immunotherapy. Clinical Pharmacology & Therapeutics 113:5, pages 963-972.
Crossref
Qing-yu Yao, Jun Zhou, Ye Yao, Jun-sheng Xue, Yu-chen Guo, Wei-zhe Jian, Ren-wei Zhang, Xiao-yan Qiu & Tian-yan Zhou. (2022) An integrated PK/PD model investigating the impact of tumor size and systemic safety on animal survival in SW1990 pancreatic cancer xenograft. Acta Pharmacologica Sinica 44:2, pages 465-474.
Crossref
Lito A. Papaxenopoulou, Gang Zhao, Sahamoddin Khailaie, Konstantinos Katsoulis-Dimitriou, Ingo Schmitz, Eva Medina, Haralampos Hatzikirou & Michael Meyer-Hermann. (2022) In silico predicted therapy against chronic Staphylococcus aureus infection leads to bacterial clearance in vivo. iScience 25:12, pages 105522.
Crossref
Mélanie Wilbaux, Shu Yang, Astrid Jullion, David Demanse, Diana Graus Porta, Andrea Myers, Christophe Meille & Yi Gu. (2022) Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model‐Informed Dose Selection in Oncology First‐in‐Human Study: A Case of Roblitinib ( FGF401 ) . Clinical Pharmacology & Therapeutics 112:6, pages 1329-1339.
Crossref
Alexandre Bordat, Tanguy Boissenot, Nada Ibrahim, Marianne Ferrere, Manon Levêque, Léa Potiron, Stéphanie Denis, Sébastien Garcia-Argote, Olivia Carvalho, Jérôme Abadie, Catherine Cailleau, Grégory Pieters, Nicolas Tsapis & Julien Nicolas. (2022) A Polymer Prodrug Strategy to Switch from Intravenous to Subcutaneous Cancer Therapy for Irritant/Vesicant Drugs. Journal of the American Chemical Society 144:41, pages 18844-18860.
Crossref
Marcus Baaz, Tim Cardilin, Floriane Lignet & Mats Jirstrand. (2022) Optimized scaling of translational factors in oncology: from xenografts to RECIST. Cancer Chemotherapy and Pharmacology 90:3, pages 239-250.
Crossref
Rocky Diegmiller, Laurent Salphati, Bruno Alicke, Timothy R. Wilson, Thomas J. Stout & Marc Hafner. (2022) Growth‐rate model predicts in vivo tumor response from in vitro data. CPT: Pharmacometrics & Systems Pharmacology 11:9, pages 1183-1193.
Crossref
Deborah Plana, Geoffrey Fell, Brian M. Alexander, Adam C. Palmer & Peter K. Sorger. (2022) Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects. Nature Communications 13:1.
Crossref
Balthazar Toussaint, Hervé Hillaireau, Emmanuel Jaccoulet, Catherine Cailleau, Pauline Legrand, Yves Ambroise & Elias Fattal. (2021) Interspecies comparison of plasma metabolism and sample stabilization for quantitative bioanalyses: Application to (R)-CE3F4 in preclinical development, including metabolite identification by high-resolution mass spectrometry. Journal of Chromatography B 1183, pages 122943.
Crossref
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations 65 128 .
Phillip Spinosa, Monika Musial‐Siwek, Marc Presler, Alison Betts, Emily Rosentrater, Janice Villali, Lucia Wille, Yang Zhao, Tom McCaughtry, Kalyanasundaram Subramanian & Hanlan Liu. (2021) Quantitative modeling predicts competitive advantages of a next generation anti‐NKG2A monoclonal antibody over monalizumab for the treatment of cancer. CPT: Pharmacometrics & Systems Pharmacology 10:3, pages 220-229.
Crossref
Mohamed Elmeliegy & Oliver Ghobrial. 2021. Remington. Remington 263 280 .
Hardik Mody, Vidya Ramakrishnan, Maher Chaar, Jovin Lezeau, Adrian Rump, Kareem Taha, Lawrence Lesko & Sihem Ait‐Oudhia. (2020) A Review on Drug‐Induced Nephrotoxicity: Pathophysiological Mechanisms, Drug Classes, Clinical Management, and Recent Advances in Mathematical Modeling and Simulation Approaches. Clinical Pharmacology in Drug Development 9:8, pages 896-909.
Crossref
Bonnie V. Dougherty & Jason A. Papin. (2020) Systems biology approaches help to facilitate interpretation of cross-species comparisons. Current Opinion in Toxicology 23-24, pages 74-79.
Crossref
Alison Betts & Piet H. van der Graaf. (2020) Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology. Clinical Pharmacology & Therapeutics 108:3, pages 528-541.
Crossref
Sara Zalba, Ana M. Contreras-Sandoval, Eva Martisova, Reno Debets, Christian Smerdou & María Jesús Garrido. (2020) Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs. Pharmaceutics 12:6, pages 595.
Crossref
Sara C. Humphreys, Mai B. Thayer, Jabbar Campbell, Wen Li Kelly Chen, Dan Adams, Julie M. Lade & Brooke M. Rock. (2020) Emerging siRNA Design Principles and Consequences for Biotransformation and Disposition in Drug Development. Journal of Medicinal Chemistry 63:12, pages 6407-6422.
Crossref
Tiffany M. Heaster, Bennett A. Landman & Melissa C. Skala. (2019) Quantitative Spatial Analysis of Metabolic Heterogeneity Across in vivo and in vitro Tumor Models. Frontiers in Oncology 9.
Crossref
Fiona Chandra, Lihi Zaks & Andy Zhu. (2019) Survival Prolongation Index as a Novel Metric to Assess Anti-Tumor Activity in Xenograft Models. The AAPS Journal 21:2.
Crossref
Eshita Khera & Greg M. Thurber. (2018) Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates. BioDrugs 32:5, pages 465-480.
Crossref